Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We have developed a graphical user interface for our Gen2Epi computational pipeline named Gen2EpiGUI. A total of 594 published whole-genome sequence datasets of Neisseria gonorrhoeae were used to validate the program. Gen2Epi facilitates an understandable analysis of N. gonorrhoeae whole-genome sequence data for users with limited bioinformatics skills.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/OLQ.0000000000001206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Australian Gonococcal Surveillance Program, 1 January to 31 March 2025.
Commun Dis Intell (2018)
February 2025
The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Au
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin.
View Article and Find Full Text PDFAntimicrobial resistance in in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study.
Lancet Reg Health West Pac
August 2025
Global HIV, Hepatitis and STI Programmes, World Health Organization (WHO), Geneva, Switzerland.
Background: The global spread of antimicrobial resistance (AMR) in threatens empiric single-dose gonorrhoea treatment. Enhanced global AMR surveillance is imperative. We report i) gonococcal antimicrobial susceptibility and resistance data from 2023 in the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (WHO EGASP) in the WHO Western Pacific Region (Cambodia, the Philippines, Viet Nam), Southeast Asian Region (Indonesia, Thailand), and African Region (Malawi, South Africa, Uganda, Zimbabwe), and ii) metadata of the gonorrhoea patients.
View Article and Find Full Text PDFCould tolerance explain an individual's eight episodes of gonococcal treatment failure with ceftriaxone? A case report.
Sex Transm Infect
September 2025
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Objectives: Describe the clinical evolution of a person with recurrent gonococcal cervicitis despite appropriate treatment and lack of reinfection.
Methods: We used the tolerance detection test to confirm that all three culture-positive gonococcal isolates were tolerant to ceftriaxone.
Results: Over a period of 6 months, a transgender man with gonococcal cervicitis experienced eight episodes of treatment failure despite receiving ceftriaxone 1 g intramuscularly on each occasion.
Prevalence of common bacterial STI pathogens and the microscopic diagnostic approach to abnormal vaginal discharge in a tertiary care hospital in Bangkok, Thailand.
PLoS One
September 2025
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
In Thailand, sexually transmitted infections (STIs) persist as a significant public health issue, notwithstanding the affordability of treatments. The primary challenge lies in diagnostic methodologies. According to the Thai National Treatment Guidelines for abnormal vaginal discharge, wet preparation using proportion of white blood cell (WBC) counts and epithelial cell (EC) guides presumptive STI treatment.
View Article and Find Full Text PDFEffectiveness of the four-component protein-based meningococcal vaccine against infections: Mounting evidence and public health implications for Canada.
Can Commun Dis Rep
August 2025
Division des maladies infectieuses, Centre hospitalier de l'Université de Montréal, Montréal, QC.
Background: In Canada, the burden of gonorrhea has been increasing steadily over the last decade with emerging multi-drug-resistant strains. There is a high genomic similarity between and .
Methods: Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®).